Cyclophosphamide and Fludarabine

DRUG3 trials

Sponsors

Guangzhou Institute of Respiratory Disease, Tongji Hospital, Shanghai Zhongshan Hospital

Conditions

Autoimmune DiseasesAutoimmune Diseases of the Nervous SystemAutoimmune EncephalitisBiliary Tract NeoplasmsCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticCholangiocarcinoma, PerihilarChronic Inflammatory Demyelinating Polyradiculoneuropathy

Early Phase 1

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

RecruitingNCT04561557

Tongji HospitalAutoimmune Diseases, Autoimmune Diseases of the Nervous System, Autoimmune Encephalitis +7

Start: 2020-09-22End: 2027-05-31Target: 36Updated: 2024-10-30

Phase 1

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Guangzhou Institute of Respiratory DiseaseLung Cancer, Nonsmall Cell, Recurrent

Start: 2017-03-21End: 2019-03-31Target: 20Updated: 2019-01-17

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer

RecruitingNCT07614061

Shanghai Zhongshan HospitalBiliary Tract Neoplasms, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic +2

Start: 2026-05-01End: 2029-12-01Target: 18Updated: 2026-05-29

Related Papers

CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.

2025-10-261 citations

Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis.

2025-10-155 citations

Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathy.

2025-05-267 citations